Skip to content

Translation of Parkinson's Disease Questionnaire -8 in Urdu Language

Urdu Version of Parkinson's Disease Questionnaire-8. A Cross-cultural Validity and Reliability Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05405153
Enrollment
50
Registered
2022-06-06
Start date
2022-05-05
Completion date
2023-01-20
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

PDQ-8, Parkinson's disease, validate .

Brief summary

Cross cultural analytical study to translate Parkinson's disease questionnaire-8 in Urdu language. Along with the translated version by evaluating its validity and reliability among the patients of Parkinson's disease. No such study has been previously conducted in Pakistan which translate this questionnaire in Urdu and follows the proper cross- culture adaptation. Condition or disease: Parkinson's disease. Convenient sampling technique would be used

Detailed description

Parkinson's Disease Questionnaire-8 (PDQ-8) is the brief version of PDQ-39 formulated to reduce the respondent burden and for convenient use in clinical settings in patients of Parkinson's disease. (PDQ-8) is the patient reported outcome measure constructed by taking one question from each of the eight domains of PDQ-39 (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. PDQ-8 will be translated into Urdu language by Beaton et al guidelines for cross cultural adaptation of tool. The validity and reliability of Urdu version of PDQ-8 will be evaluated by calculating Cronbach's alpha, intra-class correlation coefficient and Pearson/spearman rank correlation co-efficient. Continuous variables will be shown by mean and standard deviation and the categories will be demonstrated in frequency and percentage. Factor structure of the PDQ-8 will be extracted using exploratory factor analysis (EFA), utilizing principal component analysis with varimax rotation.

Interventions

None listed

Sponsors

Riphah International University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age 40-65 years * Both genders * Patients with diagnosed Idiopathic Parkinson's disease (IPD) by neurophysician * Patient able to read Urdu Language. Patients who can participate in community, patients with cognitive issue, Patients with MMSE more than 24 will be included

Exclusion criteria

* Patients with any other neurological issue * Patients who undergo brain surgery

Design outcomes

Primary

MeasureTime frameDescription
Parkinson's disease questionnaire (PDQ-8)8 monthsParkinson's disease Questionnaire-8 (PDQ-8) is the brief version of PDQ-39 formulated to reduce the respondent burden and for convenient use in clinical settings in patients of Parkinson's disease. (PDQ-8) is the patient reported outcome measure constructed by taking one question from each of the eight domains of PDQ- 39 (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort)

Secondary

MeasureTime frameDescription
Reliability of translated versions of PDQ-88 monthsTo determine the reliability of cross-culturally adapted and translated PDQ-8 in the patients with Parkinson's disease. Reliability or reproducibility refers to the ability of a measure to produce the same results when administered at two intervals between different visits of the patient. Thus, the reliability of tool will be assessed by internal consistency and test-retest reliability
Validity of translated versions of PDQ-88 monthsTo determine the validity of cross-culturally adapted and translated PDQ-8 in the patients with Parkinson's disease. Validity is how accurate the results are.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026